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Background:  Congestion is a primary driver of symptoms in acute heart failure (AHF). Relief of congestion is a critical goal of therapy. Although 
monitoring of response to therapy is accomplished through the assessment of daily weight and fluid loss, the correlation between changes in these 
variables and symptoms has not been well studied. Further, the relationship between improvement in markers of decongestion and clinical outcomes 
in AHF is uncertain.
Methods:  We analyzed data from 308 patients in the DOSE study, a multicenter randomized trial of furosemide strategies in AHF. We assessed 
relationships between 3 markers of decongestion at 72 hours (weight change, net fluid loss and % change in NTproBNP level) and relief of symptoms 
defined by the dyspnea visual analog scale AUC. We determined the relationship between each marker of congestion and 60-day outcomes defined 
as time to death, readmission or ER visit.
Results:  Subjects’ mean age was 66, mean EF was 35%. Of the 3 congestion measures assessed, % change in NTproBNP was significantly 
associated with symptom relief (p=0.01). There was no correlation between weight change or net fluid loss and symptom relief (Table). Favorable 
changes in each of the 3 markers of congestion were associated with improved clinical outcomes at 60 days (Table).
Conclusion: Decrease in NTproBNP, but not change in weight or net fluid loss, was modestly correlated with dyspnea relief. Improvements in each 
of the 3 markers were associated with improved clinical outcomes at 60 days.
Associations between 72 hour weight change, net fluid loss, % change in NT-proBNP and outcomes.
Dyspnea VAS AUC Time to death, rehospitalization or ER visit
Change at 72 hours r P-value Hazard Ratio P-value
Weight (Kg) -.04 0.54 0.97 per Kg weight lost 0.005
Net fluid loss (mL) .07 0.27 0.99 per 100 mL fluid lost 0.03
NT-proBNP (%) -.16 0.01 0.95 per 10% decrease NT-proBNP 0.02
